Charles Schwab Investment Management Inc Fibrogen Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 58,027 shares of FGEN stock, worth $20,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,027

Previous 58,035 0.01%

Holding current value

$20,309

Previous $51,000 54.9%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.33 - $1.26 $2 - $10	-8 Reduced 0.01%	58,027 $23,000
Q2 2024 Aug 12, 2024	SELL	$0.89 - $2.36 $186,129 - $493,556	-209,134 Reduced 78.28%	58,035 $51,000
Q1 2024 May 08, 2024	BUY	$0.73 - $2.73 $42,359 - $158,413	58,027 Added 27.75%	267,169 $627,000
Q3 2023 Nov 08, 2023	SELL	$0.79 - $2.83 $381,766 - $1.37 Million	-483,249 Reduced 69.79%	209,142 $179,000
Q2 2023 Aug 09, 2023	BUY	$2.49 - $20.59 $75,095 - $620,973	30,159 Added 4.55%	692,391 $1.87 Million
Q1 2023 May 11, 2023	SELL	$15.95 - $25.18 $99,703 - $157,400	-6,251 Reduced 0.94%	662,232 $12.4 Million
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $190,835 - $254,975	14,381 Added 2.2%	668,483 $10.7 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $406,911 - $521,132	35,694 Added 5.77%	654,102 $8.51 Million
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $72,325 - $118,052	-9,109 Reduced 1.45%	618,408 $6.53 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.79 $204,352 - $285,446	17,001 Added 2.78%	627,517 $7.54 Million
Q4 2021 Feb 11, 2022	BUY	$9.93 - $15.39 $582,821 - $903,285	58,693 Added 10.64%	610,516 $8.61 Million
Q3 2021 Nov 16, 2021	SELL	$10.18 - $26.64 $2.81 Million - $7.36 Million	-276,125 Reduced 33.35%	551,823 $5.64 Million
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $427,927 - $822,209	23,044 Added 2.86%	827,948 $22 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $658,719 - $1.18 Million	-21,249 Reduced 2.57%	804,904 $27.9 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $594,663 - $785,136	16,033 Added 1.98%	826,153 $30.6 Million
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $470,059 - $528,482	11,615 Added 1.45%	810,120 $33.3 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $1.56 Million - $2.05 Million	47,980 Added 6.39%	798,505 $32.4 Million
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $100,446 - $198,133	4,311 Added 0.58%	750,525 $26.1 Million
Q4 2019 Feb 07, 2020	BUY	$34.58 - $48.06 $780,193 - $1.08 Million	22,562 Added 3.12%	746,214 $32 Million
Q3 2019 Nov 08, 2019	BUY	$36.98 - $48.45 $1.28 Million - $1.68 Million	34,705 Added 5.04%	723,652 $26.8 Million
Q2 2019 Aug 09, 2019	BUY	$35.13 - $55.53 $1.85 Million - $2.92 Million	52,665 Added 8.28%	688,947 $31.1 Million
Q1 2019 May 14, 2019	BUY	$42.83 - $59.91 $1.86 Million - $2.6 Million	43,367 Added 7.31%	636,282 $34.6 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $837,352 - $1.33 Million	22,053 Added 3.86%	592,915 $27.4 Million
Q3 2018 Nov 13, 2018	BUY	$56.3 - $67.25 $5.69 Million - $6.8 Million	101,154 Added 21.54%	570,862 $34.7 Million
Q2 2018 Aug 08, 2018	BUY	$44.9 - $64.95 $3.64 Million - $5.27 Million	81,074 Added 20.86%	469,708 $29.4 Million
Q1 2018 May 07, 2018	BUY	$45.35 - $61.65 $1.23 Million - $1.67 Million	27,070 Added 7.49%	388,634 $18 Million
Q4 2017 Jan 17, 2018	BUY	$41.95 - $60.1 $1.17 Million - $1.68 Million	27,904 Added 8.36%	361,564 $17.1 Million
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $11.1 Million - $18 Million	333,660	333,660 $18 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Fibrogen Inc Transaction History